CN118902929A - 一种丹参提取物及其制备方法和应用 - Google Patents
一种丹参提取物及其制备方法和应用 Download PDFInfo
- Publication number
- CN118902929A CN118902929A CN202410876609.9A CN202410876609A CN118902929A CN 118902929 A CN118902929 A CN 118902929A CN 202410876609 A CN202410876609 A CN 202410876609A CN 118902929 A CN118902929 A CN 118902929A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- salvia miltiorrhiza
- extraction
- filter residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 125
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 title claims abstract description 102
- 238000000605 extraction Methods 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 80
- 241000304195 Salvia miltiorrhiza Species 0.000 title abstract 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000843 powder Substances 0.000 claims abstract description 41
- 239000008367 deionised water Substances 0.000 claims abstract description 28
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 24
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 claims abstract description 21
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 21
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 21
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 21
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 21
- 239000001168 astaxanthin Substances 0.000 claims abstract description 21
- 239000011259 mixed solution Substances 0.000 claims abstract description 21
- 229960003764 polydatin Drugs 0.000 claims abstract description 21
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 claims abstract description 21
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 16
- -1 fatty acid ester Chemical class 0.000 claims abstract description 15
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract description 15
- 238000000265 homogenisation Methods 0.000 claims abstract description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 13
- 229930195729 fatty acid Natural products 0.000 claims abstract description 13
- 239000000194 fatty acid Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract 4
- 244000132619 red sage Species 0.000 claims description 152
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 115
- 239000000243 solution Substances 0.000 claims description 55
- 230000002378 acidificating effect Effects 0.000 claims description 42
- 238000003756 stirring Methods 0.000 claims description 35
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 229940088598 enzyme Drugs 0.000 claims description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 24
- 108010059892 Cellulase Proteins 0.000 claims description 11
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 11
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 11
- 229940106157 cellulase Drugs 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 8
- 230000000415 inactivating effect Effects 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000003809 water extraction Methods 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 claims 10
- 235000005412 red sage Nutrition 0.000 claims 10
- 239000012752 auxiliary agent Substances 0.000 claims 4
- 235000019441 ethanol Nutrition 0.000 claims 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 abstract description 3
- 238000009792 diffusion process Methods 0.000 abstract description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 58
- 239000006286 aqueous extract Substances 0.000 description 16
- 239000002131 composite material Substances 0.000 description 16
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 11
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 11
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 11
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 6
- 229930183842 salvianolic acid Natural products 0.000 description 6
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 6
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 4
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 4
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010058156 Reperfusion arrhythmia Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N Tanshinone IIB Natural products O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
- A23L29/04—Fatty acids or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
- A23L5/32—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation using phonon wave energy, e.g. sound or ultrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/49—Solubiliser, Solubilising system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了丹参提取物及其制备方法和应用,包括以下步骤:S1、丹参粉末的制备;S2、提取助剂的制备:将羟丙基‑β‑环糊精加入去离子水中,接着加入含虎杖苷、虾青素的混合溶液,混合均匀后进行超声处理,处理完成后加入单甘油脂肪酸酯,在恒定的转速下搅拌均匀,再进行高速均质,均质完成后减压浓缩,得到提取助剂;S3、丹参水提液的制备;S4、滤渣提取液的制备;S5、丹参提取物的制备。本发明提供的丹参提取物制备方法通过将多种方法进行联合提取及加入特定的提取助剂,加强了丹参细胞内物质的释放、扩散和溶解,从而显著提高提取效率,同时加入提取助剂也减少了提取过程中丹参提取物中有效成分的稳定性,保证了丹参提取物的质量。
Description
技术领域
本发明属于植物提取方法技术领域,具体涉及丹参提取物及其制备方法和应用。
背景技术
丹参为唇形科植物丹参的干燥根和根茎,主产于山东、陕西、山西、河北、安徽、四川、江苏等地,味苦,微寒,归心、肝经,具有活血祛瘀,通经止痛,清心除烦,凉血消痈等功效。临床用于治疗胸痹心痛、脘腹胁痛、瘕积聚、热痹疼痛、疮疡肿痛等,是最常用的活血化瘀中药之一。
丹参中的化学成分主要分为脂溶性成分、水溶性成分和其它类成分,其中脂溶性成分包括丹参酮类、挥发油类等,水溶性成分主要为酚酸类,其它类成分主要有黄酮类、多糖类、无机盐类等。
近年来研究认为,丹参水溶性有效成分是活化化瘀的有效成分。例如,丹酚酸A对缺血再灌注引起的心肌细胞损伤有明显的保护作用,总丹酚酸表现较强的抗缺血再灌注心律失常作用;丹酚酸A、丹酚酸B以及总丹酚酸对小鼠脑缺血再灌注引起的脑损伤有保护作用,可以减少脑组织中MDA含量;丹酚酸抗血栓作用:丹酚酸对肝肾的保护作用;丹酚酸具有很强的抗氧化作用,可以清除超氧阴离子和释基自由基,抑制脂质过氧化反应,等等。
研究显示,丹参酚酸B易受热分解,且不耐热,在提取过程中有较多杂质析出。因此,在工业生产中对于丹参酚酸B的精制有一定难度。近年来,有关丹参酚酸B的提取工艺研究有较多报道,包括醇沉工艺、水煎煮、大孔树脂纯化等。中国专利CN112439004A公开了一种丹参提取物及其制备方法和应用,所述的丹参提取物是将丹参用亲水性溶剂与水的混合溶剂提取得到的粗提物浸膏混悬于水中后,先用石油醚萃取再用乙酸乙酯萃取,所得乙酸乙酯萃取部位即为所述丹参提取物,并且,所述丹参提取物中不含有丹参酮ⅡA和隐丹参酮。研究结果显示:该发明提供的丹参提取物在不抑制金黄色葡萄球菌生长的情况下,不仅能够抑制金黄色葡萄球菌的毒力,可降低其致病力,而且不易产生耐药,对金黄色葡萄球菌感染有显著治疗效果,可望作为活性组分用于制备抗金黄色葡萄球菌毒力的药物,为新型抗菌药物的研发奠定基础。中国专利CN109568217A公开了一种丹参提取物的制备方法及其在祛痘中的应用。该方法包括如下步骤:(1)将丹参粉碎,得到丹参粉末;(2)将重量百分比为50%~80%的乙醇溶液的pH值调节至碱性,得到碱性乙醇溶液;(3)将步骤(2)中得到的碱性乙醇溶液加入到步骤(1)中得到的丹参粉末中进行提取,得到初提液;然后将初提液的pH值调节至酸性,静置、离心,得到离心液;再将离心液用超滤膜进行超滤,得到丹参提取物。该发明的方法简单易行,条件易控制,原料利用率高,通过本发明的方法提取得到的丹参提取物中能够同时含有丹参酚酸、丹参多糖和丹参酮,能够有效控制由于皮脂分泌旺盛导致的痤疮,因此,可将其应用于祛痘类化妆品中。但上述专利均并未给出其提取方法对丹参有效成分的提取率有何提高,且对于丹参提取物中丹参酚酸B的活性是否有影响也无法知晓,其提取率还有待提高。
因此,本领域亟急一种可提高丹参提取物中有效成分提取率且对丹参酚酸B的活性影响较小的制备方法。
发明内容
针对现有技术的不足,本发明的目的在于提供一种丹参提取物及其制备方法和应用,该丹参提取物的制备方法提取率高,操作方便,获得的丹参提取物中有效成分含量高,具有极大的应用前景。
为实现上述目的,本发明提供如下技术方案:
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材进行低温粉碎,过筛,得到丹参粉末;
S2、提取助剂的制备:将羟丙基-β-环糊精加入去离子水中,接着加入含虎杖苷、虾青素的混合溶液,混合均匀后进行超声处理,处理完成后加入单甘油脂肪酸酯,在恒定的转速下搅拌均匀,再进行高速均质,均质完成后减压浓缩,得到提取助剂;
S3、丹参水提液的制备:将步骤S1中的丹参粉末加入去离子水,接着加入提取助剂,进行水提,水提完成后过滤,得到丹参水提液和滤渣,备用;
S4、滤渣提取液的制备:将步骤S3中的滤渣加入酸性乙醇溶液中,接着加入复合酶,搅拌均匀后加入提取助剂,随后进行超声处理,处理完成后灭酶、过滤,得到滤渣提取液;
S5、丹参提取物的制备:将步骤S3中的丹参水提液、步骤S4中的滤渣提取液混合均匀,减压浓缩,喷雾干燥,即得所述丹参提取物。
优选的,步骤S1中所述低温粉碎的温度为-80~-60℃,所述过筛的目数为200-400目。
在本发明中,粉碎可使丹参粉粒径大小均匀,比表面积增大,有利于提高提取率,但粉碎过细会使得丹参粉末之间易团聚,溶剂难于穿透,不利于提取,因此粉碎的目数在控制在200-400目之间。
更优选的,步骤S1中所述低温粉碎的温度为-80~-70℃,所述过筛的目数为200-300目。
在本发明中,通过低温下粉碎,使丹参内部的细胞液处理冷冻状态,可以减少丹参破碎时由于细胞液流出从而导致有效成分的损失,提高提取物中有效成分的含量。
优选的,步骤S2中所述混合溶液的制备方法如下:将5-10g虎杖苷、5-10g虾青素加入100g无水乙醇中,搅拌均匀即得;所述羟丙基-β-环糊精、去离子水、混合溶液、单甘油脂肪酸酯的质量比为20-30:200-300:50-60:5-8。
更优选的,骤S2中所述混合溶液的制备方法如下:将7-10g虎杖苷、5-8g虾青素加入100g无水乙醇中,搅拌均匀即得;所述羟丙基-β-环糊精、去离子水、混合溶液、单甘油脂肪酸酯的质量比为25-30:250-300:50-65:7-8。
优选的,步骤S2中所述超声处理的功率为200-300W,温度为40-50℃,时间为30-40min;所述搅拌的速度为200-300r/min,时间为20-30min;所述高速均质的转速为2000-3000r/min,时间为5-8min;所述减压浓缩的压力为30-40kpa,浓缩至原体积的1/2。
更优选的,步骤S2中所述超声处理的功率为250-300W,温度为45-50℃,时间为30-35min;所述搅拌的速度为250-300r/min,时间为25-30min;所述高速均质的转速为2500-3000r/min,时间为5-7min;所述减压浓缩的压力为30-35kpa,浓缩至原体积的1/2。
在本发明中,制备的提取助剂以羟丙基-β-环糊精为原料,通过加入虎杖苷、虾青素,使三者形复合物,最后加入表面活性剂单甘油脂肪酸酯,使提取助剂能有效的在提取过程中起到增溶作用,提高丹参的提取率。
优选的,步骤S3中所述丹参粉末与去离子水的质量比为1:15-25;所述提取助剂的用量为去离子水的10-20%,所述水提的温度为70-80℃,时间为2-3h。
更优选的,步骤S3中所述丹参粉末与去离子水的质量比为1:20-25;所述提取助剂的用量为去离子水的15-20%,所述水提的温度为70-75℃,时间为2.5-3h。
在本发明中,通过对丹参粉末进行水提,使丹参中大部分水溶性有效成分提取出来,如丹参素、丹酚酸A、丹酚酸B等。
优选的,步骤S4中所述酸性乙醇溶液的制备方法如下:将4-7g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热1-2h即得;所述复合酶由质量比为3:1-3的纤维素酶和β-葡萄糖苷酶混合而成。
更优选的,步骤S4中所述酸性乙醇溶液的制备方法如下:将柠檬酸加入无水乙醇中,搅拌均匀后于80℃加热1.5-2h即得;所述复合酶由质量比为3:2-3的纤维素酶和β-葡萄糖苷酶混合而成。
优选的,步骤S4中所述滤渣与酸性乙醇溶液的质量比为1:15-20,所述复合酶用量为滤渣质量的4-8%,所述提取助剂的用量为酸性乙醇溶液质量的10-20%,所述超声处理的功率为300-400W,温度为40-50℃,时间为20-30min。
更优选的,步骤S4中所述滤渣与酸性乙醇溶液的质量比为1:15-18,所述复合酶用量为滤渣质量的6-8%,所述提取助剂的用量为酸性乙醇溶液质量为15-20%,所述超声处理的功率为350-400W,温度为45-50℃,时间为20-25min。
在本发明中,将滤渣在酸性乙醇溶液中通过复合酶与超声波联用的方法,进一步提取滤渣中的有效成分,纤维素酶和β-葡萄糖苷酶可降解丹参的细胞壁,使细胞壁内的有效成分释放,同时超声处理可提高酸性乙醇溶液对基体的穿透,从而提高丹参中脂溶性有效成分的提取率,如丹参酮ⅡA、丹参酮ⅡB和隐丹参酮等。
优选的,步骤S5中所述减压浓缩的压力的30-40kpa,浓缩至原体积的1/3。
更优选的,步骤S5中所述减压浓缩的压力的30-35kpa,浓缩至原体积的1/3。
在本发明,将丹参水提液与滤渣提取液进行混合,不仅提取高丹参的利用率,使丹参提取物中同时具有水溶性有效成分和脂溶性有效成分,具有更好的抗自由基氧化性能。
本发明还保护一种如上所述方法制备得到的丹参提取物。
本发明还保护一种如上所述丹参提取物在制备护肤品、化妆品、药品或保健品中的应用。
优选的,所述护肤品或化妆品为具有氧化、美白或防晒功效的化妆品或护肤品;所述药品或保健品为具有抗皮肤老化功效的药品或保健口。
与现有技术相比,本发明具有如下的有益效果:
(1)本发明提供的丹参提取物的制备方法,首先通过低温粉碎,将丹参粉碎成粉末,有利于提高丹参提取物的提取率,随后将羟丙基-β-环糊精、虎杖苷、虾青素、单甘油脂肪酸酯在特定的方法下制备提取助剂,通过在制备丹参水提液和滤渣提取液时加入提取助剂,羟丙基-β-环糊精在提取过程中可起到良好的增溶作用,提高丹参中有效成分的提取率,虎杖苷、虾青素具有良好的抗氧化性,与羟丙基-β-环糊精可形成包合物,可减少丹参提取过程中丹参酚酸B的热分解,提高丹参提物中丹参酚酸B的活性,单甘油脂肪酸酯作为表面活性剂,使丹参粉末分散更均匀,同时有助于提取溶剂(如去离子水、酸性乙醇溶液)与丹参粉末之间的接触,促进丹参中有效物质的释放和溶解,从而提高提取效率和产率;接着在滤渣提取液制备时将复合酶与超声提取联用,从而将丹参中脂溶性有效成分的最大程度的提取出来,提高的丹参的生物利用率,最后再将丹参水提液与滤渣提取液进行混合,使制备得到的丹参提取物具有更好的抗氧化性能。
(2)本发明提供的丹参提取物的制备方法,通过将多种方法进行联合提取及加入特定的提取助剂,加强了丹参细胞内物质的释放、扩散和溶解,从而显著提高提取效率,同时加入提取助剂也减少了提取过程中丹参提取物中有效成分的稳定性,保证了丹参提取物的质量。
具体实施方式
下面将结合实施例对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材在-70℃下粉碎,过300目筛,得到丹参粉末;
S2、提取助剂的制备:将25g羟丙基-β-环糊精加入250g去离子水中,接着加入55g含虎杖苷、虾青素的混合溶液,室温下搅拌30min混合均匀,随后于250W、45℃下超声处理35min,处理完成后加入7g单甘油脂肪酸酯,在250r/min的恒定转速下搅拌25min,再在2500r/min的转速下高速均质7min,均质完成后于35kpa下减压浓缩至原体积的1/2,得到提取助剂;所述混合溶液的制备方法如下:将8g虎杖苷、7g虾青素加入100g无水乙醇中,搅拌均匀即得;
S3、丹参水提液的制备:将步骤S1中的120g丹参粉末加入2400g去离子水,接着加入360g提取助剂,于75℃下水提2.5h,水提完成后过滤,得到丹参水提液和滤渣,滤渣干燥备用;
S4、滤渣提取液的制备:将步骤S3中的滤渣加入酸性乙醇溶液中,滤渣与酸性乙醇溶液的质量比为1:18,接着加入滤渣质量的6%复合酶,搅拌均匀后加入酸性乙醇溶液质量15%的提取助剂,随后于350W、45℃下超声处理25min,处理完成后于100℃下灭酶,过滤,得到滤渣提取液;所述酸性乙醇溶液的制备方法如下:将6g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热1.5h即得;所述复合酶由质量比为3:3的纤维素酶和β-葡萄糖苷酶混合而成;
S5、丹参提取物的制备:将步骤S3中丹参水提液、步骤S4中滤渣提取液混合均匀,于35kpa下减压浓缩至原体积的1/3,喷雾干燥,即得所述丹参提取物。
实施例2
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材在-75℃下粉碎,过300目筛,得到丹参粉末;
S2、提取助剂的制备:将25g羟丙基-β-环糊精加入300g去离子水中,接着加入55g含虎杖苷、虾青素的混合溶液,室温下搅拌30min混合均匀,随后于250W、45℃下超声处理35min,处理完成后加入6g单甘油脂肪酸酯,在250r/min的恒定转速下搅拌25min,再在2500r/min的转速下高速均质6min,均质完成后于35kpa下减压浓缩至原体积的1/2,得到提取助剂;所述混合溶液的制备方法如下:将7g虎杖苷、8g虾青素加入100g无水乙醇中,搅拌均匀即得;
S3、丹参水提液的制备:将步骤S1中的110g丹参粉末加入2200g去离子水,接着加入330g提取助剂,于75℃下水提2.5h,水提完成后过滤,得到丹参水提液和滤渣,滤渣干燥备用;
S4、滤渣提取液的制备:将步骤S3中滤渣加入酸性乙醇溶液中,滤渣与酸性乙醇溶液的质量比为1:17,接着加入滤渣质量6%的复合酶,搅拌均匀后加入酸性乙醇溶液质量15%的提取助剂,随后于350W、45℃下超声处理25min,处理完成后于100℃下灭酶,过滤,得到滤渣提取液;所述酸性乙醇溶液的制备方法如下:将5g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热1.5h即得;所述复合酶由质量比为3:2纤维素酶和β-葡萄糖苷酶混合而成;
S5、丹参提取物的制备:将步骤S3中丹参水提液、步骤S4中滤渣提取液混合均匀,于35kpa下减压浓缩至原体积的1/3,喷雾干燥,即得所述丹参提取物。
实施例3
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材在-80℃下粉碎,过400目筛,得到丹参粉末;
S2、提取助剂的制备:将20g羟丙基-β-环糊精加入200g去离子水中,接着加入50g含虎杖苷、虾青素的混合溶液,室温下搅拌30min混合均匀,随后于200W、40℃下超声处理40min,处理完成后加入5g单甘油脂肪酸酯,在200r/min的恒定转速下搅拌30min,再在2000r/min的转速下高速均质5min,均质完成后于30kpa下减压浓缩至原体积的1/2,得到提取助剂;所述混合溶液的制备方法如下:将5g虎杖苷、10g虾青素加入100g无水乙醇中,搅拌均匀即得;
S3、丹参水提液的制备:将步骤S1中的100g丹参粉末加入1500g去离子水,接着加入150g提取助剂,于70℃下水提3h,水提完成后过滤,得到丹参水提液和滤渣,滤渣干燥备用;
S4、滤渣提取液的制备:将步骤S3中滤渣加入酸性乙醇溶液中,滤渣与酸性乙醇溶液的质量比为1:15,接着加入滤渣质量4%的复合酶,搅拌均匀后加入酸性乙醇溶液质量10%的提取助剂,随后于300W、40℃下超声处理30min,处理完成后于100℃下灭酶,过滤,得到滤渣提取液;所述酸性乙醇溶液的制备方法如下:将4g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热2h即得;所述复合酶由质量比为3:1的纤维素酶和β-葡萄糖苷酶混合而成;
S5、丹参提取物的制备:将步骤S3中丹参水提液、步骤S4中滤渣提取液混合均匀,于30kpa下减压浓缩至原体积的1/3,喷雾干燥,即得所述丹参提取物。
实施例4
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材在-60℃下粉碎,过200目筛,得到丹参粉末;
S2、提取助剂的制备:将30g羟丙基-β-环糊精加入300g去离子水中,接着加入60g含虎杖苷、虾青素的混合溶液,室温下搅拌30min混合均匀,随后于300W、50℃下超声处理30min,处理完成后加入8g单甘油脂肪酸酯,在300r/min的恒定转速下搅拌30min,再在3000r/min的转速下高速均质8min,均质完成后于40kpa下减压浓缩至原体积的1/2,得到提取助剂;所述混合溶液的制备方法如下:将10g虎杖苷、5g虾青素加入100g无水乙醇中,搅拌均匀即得;
S3、丹参水提液的制备:将步骤S1中的130g丹参粉末加入3250g去离子水,接着加入650g提取助剂,于80℃下水提2h,水提完成后过滤,得到丹参水提液和滤渣,滤渣干燥备用;
S4、滤渣提取液的制备:将步骤S2中滤渣加入酸性乙醇溶液中,滤渣与酸性乙醇溶液的质量比为1:20,接着加入滤渣质量8%的复合酶,搅拌均匀后加入酸性乙醇溶液质量20%的提取助剂,随后于400W、50℃下超声处理20min,处理完成后于100℃下灭酶,过滤,得到滤渣提取液;所述酸性乙醇溶液的制备方法如下:将7g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热1h即得;所述复合酶由质量比为3:3的纤维素酶和β-葡萄糖苷酶混合而成;
S5、丹参提取物的制备:将步骤S3中丹参水提液、步骤S4中滤渣提取液混合均匀,于40kpa下减压浓缩至原体积的1/3,喷雾干燥,即得所述丹参提取物。
对比例1
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材在-70℃下粉碎,过300目筛,得到丹参粉末;
S2、提取助剂的制备:将25g羟丙基-β-环糊精加入250g去离子水中,接着加入55g含虎杖苷、虾青素的混合溶液,室温下搅拌30min混合均匀,均质完成后于35kpa下减压浓缩至原体积的1/2,得到提取助剂;所述混合溶液的制备方法如下:将8g虎杖苷、7g虾青素加入100g无水乙醇中,搅拌均匀即得;
S3、丹参水提液的制备:将步骤S1中的120g丹参粉末加入2400g去离子水,接着加入360g提取助剂,于75℃下水提2.5h,水提完成后过滤,得到丹参水提液和滤渣,滤渣干燥备用;
S4、滤渣提取液的制备:将步骤S3中的滤渣加入酸性乙醇溶液中,滤渣与酸性乙醇溶液的质量比为1:18,接着加入滤渣质量的6%复合酶,搅拌均匀后加入酸性乙醇溶液质量15%的提取助剂,随后于350W、45℃下超声处理25min,处理完成后于100℃下灭酶,过滤,得到滤渣提取液;所述酸性乙醇溶液的制备方法如下:将6g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热1.5h即得;所述复合酶由质量比为3:3的纤维素酶和β-葡萄糖苷酶混合而成;
S5、丹参提取物的制备:将步骤S3中丹参水提液、步骤S4中滤渣提取液混合均匀,于35kpa下减压浓缩至原体积的1/3,喷雾干燥,即得所述丹参提取物。
对比例2
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材在-70℃下粉碎,过300目筛,得到丹参粉末;
S2、提取助剂的制备:将7g单甘油脂肪酸酯加入250g去离子水中,接着加入55g含虎杖苷、虾青素的混合溶液,在250r/min的恒定转速下搅拌25min,再在2500r/min的转速下高速均质7min,均质完成后于35kpa下减压浓缩至原体积的1/2,得到提取助剂;所述混合溶液的制备方法如下:将8g虎杖苷、7g虾青素加入100g无水乙醇中,搅拌均匀即得;
S3、丹参水提液的制备:将步骤S1中的120g丹参粉末加入2400g去离子水,接着加入360g提取助剂,于75℃下水提2.5h,水提完成后过滤,得到丹参水提液和滤渣,滤渣干燥备用;
S4、滤渣提取液的制备:将步骤S3中的滤渣加入酸性乙醇溶液中,滤渣与酸性乙醇溶液的质量比为1:18,接着加入滤渣质量的6%复合酶,搅拌均匀后加入酸性乙醇溶液质量15%的提取助剂,随后于350W、45℃下超声处理25min,处理完成后于100℃下灭酶,过滤,得到滤渣提取液;所述酸性乙醇溶液的制备方法如下:将6g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热1.5h即得;所述复合酶由质量比为1:1的纤维素酶和β-葡萄糖苷酶混合而成;
S5、丹参提取物的制备:将步骤S3中丹参水提液、步骤S4中滤渣提取液混合均匀,于35kpa下减压浓缩至原体积的1/3,喷雾干燥,即得所述丹参提取物。
对比例3
一种丹参提取物的制备方法,包括以下步骤:
S1、丹参粉末的制备:将丹参药材在-70℃下粉碎,过300目筛,得到丹参粉末;
S2、丹参水提液的制备:将步骤S1中的120g丹参粉末加入2400g去离子水于75℃下水提2.5h,水提完成后过滤,得到丹参水提液和滤渣,滤渣干燥备用;
S3、滤渣提取液的制备:将步骤S2中的滤渣加入酸性乙醇溶液中,滤渣与酸性乙醇溶液的质量比为1:18,接着加入滤渣质量的6%复合酶,搅拌均匀,随后于350W、45℃下超声处理25min,处理完成后于100℃下灭酶,过滤,得到滤渣提取液;所述酸性乙醇溶液的制备方法如下:将6g柠檬酸加入100g无水乙醇中,搅拌均匀后于80℃加热1.5h即得;所述复合酶由质量比为3:3的纤维素酶和β-葡萄糖苷酶混合而成;
S4、丹参提取物的制备:将步骤S2中丹参水提液、步骤S3中滤渣提取液混合均匀,于35kpa下减压浓缩至原体积的1/3,喷雾干燥,即得所述丹参提取物。
分别计算实施例1-4和对比例1-3中得到的丹参提取物的提取率,其中,提取率=(丹参提取物的重量/丹参粉末的重量)×100%,同时测试丹参提取物中丹酚酸B、丹参酮ⅡA以及隐丹参酮的含量,各物质含量=化合物的重量/丹参粉末的重量(mg/g),结果如下表1:
表1
从上表1中可以看出,本发明提供的丹参提取物的制备方法显著提高了提取率,同时提取物中的丹酚酸B、丹参酮ⅡA以及隐丹参酮含量较高。
将实施例1和对比例1-3制备得到的丹参提取物进行抗氧化性能和抗菌性测试,具体如下:将丹参提取物配制成质量浓度为1%的溶液,准确称取DPPH,用无水乙醇溶解并稀释至2×10-4mol/L,随后将3mL丹参提取物溶液加入10mL DPPH溶液中,振荡摇匀,室温下避光反应30min,在517nm处测定吸光度(Ai),以Vc作为阳性对照,同时以3mL丹参提取物溶液加入10mL无水乙醇测得吸光度(Aj),再取3mL无水乙醇代替样品加入10mL DPPH自由基溶液测得空白吸光度(Ao),抗菌性测试:将金黄色葡萄球菌接种至灭菌的培养基中,36℃培养24h,再用灭菌生理盐水稀释至103-105CFU·mL-1,采用滤纸片浸渍法测定抑菌圈直径,将定性滤纸圆片置于离心管中,高压灭菌后,干燥,备用;将质量浓度为1%的丹参提取物溶液加入含定性滤纸圆片的离心管中,浸泡30min;将灭菌培养基倒入培养皿中,紫外灭菌冷却后,加入103-105CFU·mL-1菌悬液20μL,涂布均匀,用无菌镊子夹取浸有丹参提取物溶液的滤纸圆片,略干后放入培养皿中;将培养皿于36℃培养24h,用游标卡尺测定抑菌圈直径。测试结果如下表2:
表2表2
| DPPH自由基清除率/% | 抑菌圈直径/mm | |
| 实施例1 | 91.3 | 17.33 |
| 对比例1 | 81.5 | 13.67 |
| 对比例2 | 78.6 | 12.89 |
| 对比例3 | 74.2 | 10.23 |
从上表2可以看出,本发明制备得到的丹参提取物具有显著的自由基清除率和抑菌性,具有良好的应用前景。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (10)
1.一种丹参提取物的制备方法,其特征在于,包括以下步骤:
S1、丹参粉末的制备:将丹参药材进行低温粉碎,过筛,得到丹参粉末;
S2、提取助剂的制备:将羟丙基-β-环糊精加入去离子水中,接着加入含虎杖苷、虾青素的混合溶液,混合均匀后进行超声处理,处理完成后加入单甘油脂肪酸酯,在恒定的转速下搅拌均匀,再进行高速均质,均质完成后减压浓缩,得到提取助剂;
S3、丹参水提液的制备:将步骤S1中的丹参粉末加入去离子水,接着加入提取助剂,进行水提,水提完成后过滤,得到丹参水提液和滤渣,备用;
S4、滤渣提取液的制备:将步骤S3中的滤渣加入酸性乙醇溶液中,接着加入复合酶,搅拌均匀后加入提取助剂,随后进行超声处理,处理完成后灭酶、过滤,得到滤渣提取液;
S5、丹参提取物的制备:将步骤S3中的丹参水提液、步骤S4中的滤渣提取液混合均匀,减压浓缩,喷雾干燥,即得所述丹参提取物。
2.根据权利要求1所述的制备方法,其特征在于,步骤S1中所述低温粉碎的温度为-80~-60℃。
3.根据权利要求1所述的制备方法,其特征在于,步骤S2中所述混合溶液的制备方法如下:将5-10g虎杖苷、5-10g虾青素加入100g无水乙醇中,搅拌均匀即得;所述羟丙基-β-环糊精、去离子水、混合溶液、单甘油脂肪酸酯的质量比为20-30:200-300:50-60:5-8。
4.根据权利要求1所述的制备方法,其特征在于,步骤S2中所述超声处理的功率为200-300W,温度为40-50℃,时间为30-40min;所述搅拌的速度为200-300r/min,时间为20-30min;所述高速均质的转速为2000-3000r/min,时间为5-8min;所述减压浓缩的压力为30-40kpa,浓缩至原体积的1/2。
5.根据权利要求1所述的制备方法,其特征在于,步骤S3中所述丹参粉末与去离子水的质量比为1:15-25;所述提取助剂的用量为去离子水的10-20%,所述水提的温度为70-80℃,时间为2-3h。
6.根据权利要求1所述的制备方法,其特征在于,步骤S4中所述酸性乙醇溶液的制备方法如下:将柠檬酸加入无水乙醇中,搅拌均匀后于80℃加热1-2h即得;所述复合酶由质量比为3:1-3的纤维素酶和β-葡萄糖苷酶混合而成。
7.根据权利要求1所述的制备方法,其特征在于,步骤S4中所述滤渣与酸性乙醇溶液的质量比为1:15-20,所述复合酶用量为滤渣质量的4-8%,所述提取助剂的用量为酸性乙醇溶液质量的10-20%,所述超声处理的功率为300-400W,温度为40-50℃,时间为20-30min。
8.根据权利要求1所述的制备方法,其特征在于,步骤S5中所述减压浓缩的压力的30-40kpa,浓缩至原体积的1/3。
9.一种如权利要求1-8任一项所述方法制备得到的丹参提取物。
10.一种如权利要求9所述丹参提取物在制备护肤品、化妆品、药品或保健品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410876609.9A CN118902929A (zh) | 2024-07-02 | 2024-07-02 | 一种丹参提取物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410876609.9A CN118902929A (zh) | 2024-07-02 | 2024-07-02 | 一种丹参提取物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118902929A true CN118902929A (zh) | 2024-11-08 |
Family
ID=93305563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410876609.9A Pending CN118902929A (zh) | 2024-07-02 | 2024-07-02 | 一种丹参提取物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118902929A (zh) |
-
2024
- 2024-07-02 CN CN202410876609.9A patent/CN118902929A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112957379B (zh) | 一种积雪草提取物的提取方法 | |
| CN105254775B (zh) | 芦荟多糖提取方法和芦荟润肤组合物 | |
| CN103006527A (zh) | 一种祛痘液 | |
| CN113521164B (zh) | 一种具有抑菌作用的藏药组合物及其制备方法和应用 | |
| CN111088127B (zh) | 一种青蒿手工皂及其制备方法 | |
| CN105148288A (zh) | 一种环糊精以及改性环糊精辅助提取中药有效成分的方法 | |
| CN111000955A (zh) | 一种紧致抑菌凝胶及其制备方法 | |
| CN117344399B (zh) | 一种含植物活性成分的大生物涤纶纤维及其制备方法 | |
| CN102961414A (zh) | 中草药原浆及其应用 | |
| CN118902929A (zh) | 一种丹参提取物及其制备方法和应用 | |
| CN112494408A (zh) | 美白消炎面膜液及其制备方法 | |
| CN103505398B (zh) | 一种连翘叶面膜 | |
| CN114652658A (zh) | 一种中药提取物组合物及其应用、一种中药提取物凝胶免洗面膜及其制备方法 | |
| CN114886834A (zh) | 美白精华液及其制备方法 | |
| CN105311328A (zh) | 一种治疗妇科炎症的中药组合物及其应用 | |
| CN1258451A (zh) | 纯中药防治病毒制剂 | |
| CN112891431A (zh) | 一种植物生发组合物、制剂及其制备方法 | |
| CN117257688B (zh) | 一种化妆品用除螨剂 | |
| CN119454861B (zh) | 一种治疗痔疮的中药组合物的制备方法与应用 | |
| CN116440192B (zh) | 一种防治运动型心肌损伤的中药组合物及其制备方法和应用 | |
| CN109010187A (zh) | 一种用于治疗痤疮的面霜及其制备方法 | |
| CN100446754C (zh) | 蛇脂冰肤软膏的制备方法 | |
| CN108542934A (zh) | 一种防治粉刺皮肤病的外用中药擦剂及其制备方法 | |
| CN117357620A (zh) | 一种排湿止痒方组方及提取工艺 | |
| CN108721425B (zh) | 一种清肺的穴位敷膏及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |